Roche's Erivedge gets EU conditional approval
This article was originally published in Scrip
Executive Summary
The EU has granted a conditional approval to Roche's hedgehog pathway inhibitor Erivedge (vismodegib) for use in advanced basal cell carcinoma following a CHMP positive opinion in April, making it the first once-daily capsule treatment for this indication.